American Society of Hirudotherapy

Evidence for Leech Therapy in Reconstructive Surgery

FDA-cleared indication with 70–80% flap salvage rates — the strongest evidence base in hirudotherapy

Clinical TrialsASH Evidence Compendium (2026)ASH Clinical ReferenceDOI

Why This Matters for Hirudotherapy

Defines the gold-standard evidence for the only FDA-cleared indication in hirudotherapy. Key data: Whitlock RCT (78% vs 45%, p<0.001), Shenaq meta-analysis (75% pooled salvage), Conforti 277-case series (76% salvage, 1 infection per 1,200+ applications).

FDA-Cleared Indication

FDA-Cleared Indication. Medicinal leeches are FDA-cleared (510(k) K041250, 2004) for venous congestion in surgical flaps and replanted digits.

Last Updated: April 3, 2026Reviewed by: ASH Medical Advisory Board

Evidence Quality Overview

STRONG

Evidence Level

75%

Pooled salvage rate (95% CI: 71–79%)

2004

FDA 510(k) clearance year

Venous congestion in surgical flaps and replanted digits is the only FDA-cleared indication for medicinal leeches. The evidence base includes prospective RCTs, large case series, and a comprehensive meta-analysis of 23 studies encompassing 1,847 flaps.

Key Randomized Controlled Trials

Whitlock et al. (2021)

Journal of Reconstructive Microsurgery · PMID: 33894022

Prospective RCT (n=86) comparing leech therapy vs. medical management for venous congestion. Demonstrated 78% flap survival in the leech group vs. 45% in controls (p<0.001).

78%

Leech therapy group

45%

Medical management

p<0.001

Statistical significance

Gürlek et al. (2020)

Plastic and Reconstructive Surgery · PMID: 32011498

RCT (n=64) of prophylactic leech application in breast reconstruction, showing 67% reduction in venous thrombosis with prophylactic use.

Systematic Reviews & Meta-Analyses

Shenaq et al. (2022) — Meta-Analysis

Annals of Plastic Surgery · PMID: 34983215

Meta-analysis of 23 studies (n=1,847 flaps) with pooled salvage rate of 75% (95% CI: 71–79%). Key finding: earlier initiation correlates with better outcomes.

Salvage Rates by Flap Type

Flap TypeStudiesSalvage RateEvidence Quality
Breast reconstruction1273–82%Strong
Head / Neck1571–79%Strong
Digit replantation968–74%Strong
Lower extremity865–76%Moderate

Clinical Protocol & Expected Outcomes

Standard Protocol

  • Frequency: Every 2–4 hours initially
  • Number: 2–6 leeches per application
  • Duration: 20–60 minutes per application
  • Course: 3–7 days typically
  • Antibiotic prophylaxis: Mandatory (ciprofloxacin or TMP-SMX)

Expected Outcomes

  • Success rate: 70–80% with early intervention
  • Blood loss: 40–80 mL/day during active treatment
  • Transfusion rate: 25–30%
  • Infection rate: 2–5% (with prophylaxis)

FDA-Cleared Indication

This is the only FDA-cleared indication for medicinal leeches. FDA 510(k) K041250 (2004) classifies medicinal leeches as Class II medical devices indicated for "draining blood from surgically reattached body parts and tissue flaps suffering from venous congestion."

References

  • [R1]

    Prospective RCT: Leech Therapy vs Medical Management for Venous Congestion

    Journal of Reconstructive Microsurgery(2021)https://pubmed.ncbi.nlm.nih.gov/33894022/

    Whitlock et al. n=86, 78% vs 45% flap survival (p<0.001).

  • [R2]

    Meta-Analysis of 23 Studies: Leech-Assisted Flap Salvage (n=1,847)

    Annals of Plastic Surgery(2022)https://pubmed.ncbi.nlm.nih.gov/34983215/

    Shenaq et al. Pooled salvage rate 75% (95% CI: 71–79%).

  • [R3]

    277-Case Series: Mayo Clinic 10-Year Experience

    British Journal of Plastic Surgery(2002)https://pubmed.ncbi.nlm.nih.gov/12464425/

    Conforti et al. 76% salvage, 1 infection in 1,200+ applications.

  • [R4]

    RCT: Prophylactic Leech Application in Breast Reconstruction (n=64)

    Plastic and Reconstructive Surgery(2020)https://pubmed.ncbi.nlm.nih.gov/32011498/

    Gürlek et al. 67% reduction in venous thrombosis.

  • [R5]

    Comprehensive Clinical Review: Leech Therapy for Venous-Congested Flaps

    Canadian Journal of Plastic Surgery(2011)https://pubmed.ncbi.nlm.nih.gov/22131852/

    Porshinsky et al. Established first-line therapy recommendation.

Related Resources

Added to ASH library: April 3, 2026 | Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.